Why Farbe Firma is the Top Manufacturer of Ethylmethylhydroxypyridine Succinate Injection
- Maulik Sudani
- Jun 2
- 7 min read
Last Updated: June 2, 2026
TL;DR: Ethylmethylhydroxypyridine Succinate Injection — a sterile clear solution of the antioxidant and membrane-protective neuroprotective emoxypine succinate, supplied most commonly as a 50 mg/mL solution in 2 mL and 5 mL ampoules for slow intravenous or intramuscular administration — is widely used in the CIS and allied markets for acute and chronic cerebral circulatory disorders, including the acute phase of ischaemic cerebrovascular accident, dyscirculatory (chronic ischaemic) encephalopathy, cognitive and vegetative-dystonia disorders, anxiety states and the consequences of acute intoxication. By scavenging free radicals, stabilising cell membranes and improving tissue oxygen utilisation under hypoxia, it acts as an antioxidant, anti-hypoxant and neuroprotective agent. Because it is a ready-to-use aqueous ampoule solution, its safety depends on accurate assay, a controlled impurity profile, low particulate and endotoxin, robust ampoule container-closure integrity and protection from light. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Ethylmethylhydroxypyridine Succinate Injection at our Gujarat, India facility and supplies it to hospital pharmacy, neurology and critical-care services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Antioxidant / anti-hypoxant neuroprotective — Ethylmethylhydroxypyridine Succinate Injection (emoxypine succinate) is used for acute and chronic cerebral circulatory disorders, including acute ischaemic cerebrovascular accident, dyscirculatory encephalopathy, cognitive and vegetative-dystonia disorders and anxiety states, acting by scavenging free radicals, stabilising cell membranes and improving tissue oxygen utilisation under hypoxia.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, qualified ampoule filling and sealing lines, dedicated control of assay, related substances, particulate and endotoxin for a ready-to-use aqueous solution, with container-closure integrity (dye-ingress / vacuum) verification and protection from light on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, drug master files and CEP-style documentation for registrations including ministry-of-health, neurology-formulary and hospital tenders.
End-to-end CDMO services: Contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tender-ready ampoule packaging and logistics coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Ethylmethylhydroxypyridine Succinate Injection Demands a Premium Manufacturer
Ethylmethylhydroxypyridine Succinate Injection — the antioxidant neuroprotective known generically as emoxypine succinate — occupies an important place in neurology and critical-care practice across the CIS, Eastern European, MENA and allied markets. Neurologists and intensivists reach for it in the acute phase of an ischaemic cerebrovascular accident, in dyscirculatory (chronic ischaemic) encephalopathy, in cognitive impairment and vegetative-dystonia syndromes, in anxiety states, and in the consequences of acute intoxication and hypoxic injury. It is given by slow intravenous infusion or by deep intramuscular injection, and in many of these settings the patient is acutely unwell, so the dose must be accurately delivered from an ampoule that is clean, particulate-free and reliably sealed.
That clinical reality places real demands on the manufacturer. Although the molecule itself is a small, water-soluble succinate salt rather than a complex biologic, a ready-to-use aqueous ampoule solution carries its own discipline: the assay must be exact and held across the shelf life, the impurity and degradation profile must be controlled, the solution must remain clear and free of visible and sub-visible particulate, endotoxin must be held well within limits, and the glass ampoule must be hermetically sealed and verified for container-closure integrity so that sterility is maintained to the point of use. The product is also light-sensitive and is protected through its packaging. Choosing an Ethylmethylhydroxypyridine Succinate Injection manufacturer that treats assay accuracy, impurity control, particulate and endotoxin limits and ampoule integrity as core engineering disciplines is what protects the patient at the bedside.
What Sets a World-Class Ethylmethylhydroxypyridine Succinate Injection Manufacturer Apart
A world-class manufacturer of Ethylmethylhydroxypyridine Succinate Injection invests in three areas that weaker suppliers underfund: an exact, stability-indicating assay and a tightly controlled impurity profile by HPLC for a small molecule whose degradation must be held across a multi-year shelf life, robust ampoule filling and fusion sealing with verified container-closure integrity, and tender-ready dossier support for a product procured largely through hospital, neurology-formulary and ministry-of-health channels. It starts with the active — pharmacopoeial- or in-house-specification-grade emoxypine succinate sourced from qualified, audited API makers, with full impurity profiling, assay and certificates of analysis verified by the receiving laboratory before the material enters production.
Formulation, filling and sealing then have to preserve both the assay and the dose. The bulk solution is compounded in water-for-injection at controlled pH, sterile-filtered through 0.22 µm membrane and filled aseptically into clear-glass ampoules under ISO Class 5 air, with the option of terminal sterilisation where the formulation and container permit. Each ampoule is fusion-sealed and then 100 % inspected — by automated and manual methods — for particulate matter, fill volume, seal quality and cosmetic defects. The filling and sealing parameters are locked in the master batch record; in-process and release testing confirm assay by HPLC, the impurity profile, pH, clarity and colour of the solution, and container-closure integrity is verified by dye-ingress or vacuum testing so that every sealed ampoule protects the patient.
Quality Systems Behind Every Ethylmethylhydroxypyridine Succinate Injection
Every Farbe Firma Ethylmethylhydroxypyridine Succinate Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay against pharmacopoeial or validated in-house reference standards, control of related substances and degradation products by HPLC, pH and osmolarity, clarity and colour of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, fill-volume verification and container-closure integrity for the 2 mL and 5 mL ampoule formats. Certificates of analysis are issued with full traceability back to the API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, calibrated sterilisation and depyrogenation equipment, validated ampoule filling and sealing lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because the product is a light-sensitive aqueous solution whose assay and impurity profile drive both efficacy and shelf life, we treat the stability-indicating HPLC assay and the particulate result as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (30 °C / 65 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and the product is protected from light through its primary and secondary packaging.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Ethylmethylhydroxypyridine Succinate Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables across neurology, critical-care, anti-infective, anaesthesia and supportive-care categories. For Ethylmethylhydroxypyridine Succinate Injection specifically, we supply a 50 mg/mL solution in 2 mL and 5 mL ampoules under WHO-GMP conditions, with country-specific strengths, fill volumes and pack configurations available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the assay, impurity-profile and stability data package — ready to hand for registration.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics. When a buyer needs Ethylmethylhydroxypyridine Succinate Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, ampoule-line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the ampoule suite; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API impurity sourcing, stability-indicating assay development, particulate and endotoxin control, ampoule container-closure integrity, photostability and shelf-life choices in real detail. For an antioxidant neuroprotective given to acutely unwell neurology and critical-care patients, where assay accuracy and ampoule integrity directly govern safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Ethylmethylhydroxypyridine Succinate Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Ethylmethylhydroxypyridine Succinate Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, qualified ampoule filling and sealing lines, qualified water-for-injection systems, 100 % ampoule inspection and continuous environmental monitoring.
Which strengths and pack sizes of Ethylmethylhydroxypyridine Succinate Injection do you supply?
Our standard presentation is a 50 mg/mL solution (emoxypine succinate) in 2 mL and 5 mL clear-glass ampoules. Custom strengths, fill volumes, ampoule counts per pack and country-specific artwork are available under contract manufacturing agreements.
Can Farbe Firma support country-specific registrations for Ethylmethylhydroxypyridine Succinate Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
How does Farbe Firma assure the quality and safety of Ethylmethylhydroxypyridine Succinate Injection?
We control assay and related substances by stability-indicating HPLC against pharmacopoeial or validated in-house standards, verify pH, clarity and colour, hold endotoxin well within limits by LAL, run particulate and sterility testing, 100 %-inspect every ampoule, verify container-closure integrity by dye-ingress or vacuum testing, protect the product from light, and qualify each batch against ICH Q1A and ICH Q1B protocols.
What is the minimum order quantity for Ethylmethylhydroxypyridine Succinate Injection contract manufacturing?
MOQs vary by ampoule size, fill volume, label complexity and dossier requirements. For the 2 mL and 5 mL presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments